Midaglizole hydrochloride is a potent α2-adrenoceptor antagonist with higher affinity for α2-adrenoceptors (pKi = 6.28) than for α1-adrenoceptors (7.4-fold selectivity); it inhibits [3H]clonidine binding more effectively than [3H]prazosin binding in rat cerebral cortex membranes; stimulates insulin release from rat islets (EC50 = 200 nM) and MIN6 β-cells (EC50 = 24 μM); inhibits KATP currents in Kir6.2 (IC50 = 3.8 μM) and Kir6.2/SUR1 (IC50 = 4.4 μM); and increases blood pressure in pithed rats when administered intravenously at 3 and 30 mg/kg.